-transparent.png){kind=logo}
Acute exposure to cigarette smoke causes airway hyperresponsiveness (AHR) in guinea-pigs, which resolves within a few hours. Repeated exposure may have a different effect on the airways. To address this question, guinea-pigs were repeatedly exposed to cigarette smoke (six cigarettes for 1 h x day(-1)) for 14 consecutive days. Airway responsiveness to inhaled histamine and differential cell counts in bronchoalveolar lavage fluid (BALF) were evaluated 1 day after the last exposure. Significant neutrophilia in BALF was observed after 3 days of smoke exposure. Significant eosinophilia in BALF and AHR were observed after 14 days of smoke exposure, but not after 3 or 7 days of smoke exposure. These changes persisted until 3 days after the last exposure and resolved 7 days afterwards. Histologically, the recruited eosinophils were observed predominantly in the airways, but not in the alveoli. Treatment with E-6123, a specific platelet-activating factor receptor antagonist (1 mg x kg(-1) x day(-1) p.o. during smoke exposure) significantly inhibited the eosinophil influx and AHR. Repeated exposure to cigarette smoke may induce prolonged airway inflammation and airway hyperresponsiveness in guinea-pigs. Platelet-activating factor or platelet-activating factor-like lipids may play a key role in airway hyperresponsiveness, presumably by the induction of eosinophilic airway inflammation.
K Matsumoto, and
H Aizawa, and
H Inoue, and
H Koto, and
S Takata, and
M Shigyo, and
H Nakano, and
N Hara
November 2014,
Acta pharmacologica Sinica,
K Matsumoto, and
H Aizawa, and
H Inoue, and
H Koto, and
S Takata, and
M Shigyo, and
H Nakano, and
N Hara
April 2015,
Inflammation,
K Matsumoto, and
H Aizawa, and
H Inoue, and
H Koto, and
S Takata, and
M Shigyo, and
H Nakano, and
N Hara
July 2011,
Translational research : the journal of laboratory and clinical medicine,
K Matsumoto, and
H Aizawa, and
H Inoue, and
H Koto, and
S Takata, and
M Shigyo, and
H Nakano, and
N Hara
January 2021,
BMC pulmonary medicine,
K Matsumoto, and
H Aizawa, and
H Inoue, and
H Koto, and
S Takata, and
M Shigyo, and
H Nakano, and
N Hara
January 1997,
Nihon Kyobu Shikkan Gakkai zasshi,
K Matsumoto, and
H Aizawa, and
H Inoue, and
H Koto, and
S Takata, and
M Shigyo, and
H Nakano, and
N Hara
February 2018,
International immunopharmacology,
K Matsumoto, and
H Aizawa, and
H Inoue, and
H Koto, and
S Takata, and
M Shigyo, and
H Nakano, and
N Hara
April 2020,
Experimental cell research,
K Matsumoto, and
H Aizawa, and
H Inoue, and
H Koto, and
S Takata, and
M Shigyo, and
H Nakano, and
N Hara
January 2015,
International journal of clinical and experimental medicine,
K Matsumoto, and
H Aizawa, and
H Inoue, and
H Koto, and
S Takata, and
M Shigyo, and
H Nakano, and
N Hara
June 2015,
The European respiratory journal,
K Matsumoto, and
H Aizawa, and
H Inoue, and
H Koto, and
S Takata, and
M Shigyo, and
H Nakano, and
N Hara
January 2013,
PloS one,
